Favorable News Coverage Somewhat Unlikely to Affect Nektar Therapeutics (NKTR) Stock Price
Press coverage about Nektar Therapeutics (NASDAQ:NKTR) has trended positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Nektar Therapeutics earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.3734108311749 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Bristol-Myers Squibb Looks For Growth Of Opdivo Beyond … – Seeking Alpha (seekingalpha.com)
- Bristol-Myers and Nektar Therapeutics to jointly develop cancer treatments – MarketWatch (marketwatch.com)
- BMS antes up with Nektar deal worth $3.6B (medcitynews.com)
- Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock (Revised) (finance.yahoo.com)
- Recent BMY News (bloomberg.com)
Nektar Therapeutics (NASDAQ NKTR) traded up $1.29 during midday trading on Friday, reaching $83.43. 2,340,000 shares of the company traded hands, compared to its average volume of 3,030,000. Nektar Therapeutics has a twelve month low of $12.50 and a twelve month high of $99.02. The company has a current ratio of 4.14, a quick ratio of 3.99 and a debt-to-equity ratio of 2.91. The firm has a market cap of $13,140.00, a P/E ratio of -117.51 and a beta of 2.04.
In related news, CEO Howard W. Robin sold 83,333 shares of Nektar Therapeutics stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $55.69, for a total value of $4,640,814.77. Following the completion of the sale, the chief executive officer now owns 272,768 shares of the company’s stock, valued at approximately $15,190,449.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Christopher A. Kuebler sold 30,000 shares of Nektar Therapeutics stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $58.66, for a total transaction of $1,759,800.00. Following the completion of the sale, the director now directly owns 70,500 shares of the company’s stock, valued at approximately $4,135,530. The disclosure for this sale can be found here. In the last three months, insiders sold 196,666 shares of company stock valued at $12,718,923. 6.10% of the stock is currently owned by insiders.
WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2018/02/18/favorable-news-coverage-somewhat-unlikely-to-affect-nektar-therapeutics-nktr-stock-price.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.